- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ruxolitinib Cream Shows Promise in Treating Adolescent Atopic Dermatitis: Study
USA: In a groundbreaking development in dermatology, the efficacy, safety, and long-term disease control of Ruxolitinib Cream among adolescents with Atopic Dermatitis (AD) have been showcased through pooled results from two randomized Phase 3 studies. The findings of these studies offer hope to millions of adolescents grappling with the distressing symptoms of AD.
The study, published in the American Journal of Clinical Dermatology, showed that 1.5% ruxolitinib cream may result in significant anti-inflammatory and antipruritic effects within the subset of adolescent patients with atopic dermatitis. Long-term, as-needed utilization of the drug is well tolerated and maintains disease control.
Atopic Dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching, redness, and dryness. While it affects individuals of all ages, adolescents often experience profound psychological and social impacts due to the visible nature of the condition.
A topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor, demonstrated efficacy and safety among adolescents/adults in two phase 3 studies (TRuE-AD1/TRuE-AD2). Lawrence F. Eichenfield, Rady Children’s Hospital, San Diego, CA, USA, and colleagues aimed to describe the efficacy and safety of 1.5% ruxolitinib cream versus vehicle and long-term disease control of ruxolitinib cream among adolescents aged 12–17 years from pooled phase 3 study data.
For this purpose, the researchers included patients [≥ 12 years old with AD for ≥ 2 years, Investigator’s Global Assessment score (IGA) 2/3, and 3–20% affected body surface area (BSA) at baseline]. They were randomized in a 2:2:1 ratio to ruxolitinib cream (0.75%/1.5%) or vehicle for eight weeks of continuous use followed by a long-term safety (LTS) period of up to 52 weeks with as-needed use.
Patients who were originally applying the vehicle were randomized 1:1 to 0.75%/1.5% ruxolitinib cream. Efficacy measures in the 8th week included ≥ 75% improvement in Eczema Area and Severity Index (EASI-75), IGA treatment success (IGA-TS; i.e., score of 0/1 with ≥ 2-grade improvement from baseline), and ≥ 4-point improvement in itch numerical rating scale (NRS4).
Disease control measures during the LTS period included an IGA score of 0 (clear) or 1 (almost clear) and a percentage that affected BSA. Safety assessment was done throughout the study.
The study revealed the following findings:
· Of 1249 randomized patients, 19.6% were 12–17 years. Of these, 45 patients were randomized to vehicle and 92 patients to 1.5% ruxolitinib cream.
· A total of 75.9% of patients continued on 1.5% ruxolitinib cream in the LTS period [89.1% continued on 1.5% ruxolitinib cream; 48.9% patients on the vehicle were reassigned to 1.5% ruxolitinib cream], and 79.8% of these patients completed the LTS period.
· At week 8, substantially more patients who applied 1.5% ruxolitinib cream versus vehicle achieved IGA-TS (50.6% versus 14.0%), NRS4 (52.1% versus 17.4%), and EASI-75 (60.9% versus 34.9%).
· The mean reduction in itch NRS scores was significantly greater in patients applying 1.5% ruxolitinib cream versus vehicle from day 2 [− 0.9 versus −0.2].
· During the LTS period, mean trough steady-state ruxolitinib plasma concentrations at weeks 12/52 were 27.2/15.5 nM.
· The percentage of patients achieving an IGA score of 0 or 1 was sustained or further increased with 1.5% ruxolitinib cream; the mean affected BSA was generally low (< 3%; i.e., mild disease).
· Through 52 weeks, application site reactions occurred in 1.8% of adolescent patients applying 1.5% ruxolitinib cream at any time; no patients had severe adverse events.
· There were no serious infections, major adverse cardiovascular events, malignancies, or thromboembolic events.
The findings suggest that in adolescents with atopic dermatitis, 1.5% ruxolitinib cream demonstrated antipruritic and anti-inflammatory effects, which were comparable with those in the overall study population.
Furthermore, adolescents maintained disease control over 52 weeks with as-needed use, and ruxolitinib cream was well tolerated.
Reference:
Eichenfield, L.F., Simpson, E.L., Papp, K. et al. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. Am J Clin Dermatol (2024). https://doi.org/10.1007/s40257-024-00855-2
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751